We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




PSA Can Help Identify Cancer Following Surgery for Benign Prostatic Hyperplasia

By HospiMedica International staff writers
Posted on 09 Jul 2009
Men undergoing surgical interventions for benign prostatic hyperplasia (BPH) are still at risk for subsequent development of prostate cancer due to residual tissue, claims a new study. More...


Researchers at Northwestern University (Chicago, IL, USA) conducted a retrospective review of 525 patients who had undergone one of three procedures for BPH: transurethral resection of the prostate (TURP; 343 patients), holmium laser resection of the prostate (HoLRP; 54 patients), or open prostatectomy (OP; 68 patients), between 1992 and 2007. The prostate-specific antigen (PSA) and PSA velocity values were collected at regular intervals both pre- and postoperatively for all patients, since the researchers hypothesized that the PSA level might be influenced by the efficacies of different BPH procedures. Only patients with histologic BPH and those with incidental prostate cancer who underwent a watchful waiting strategy were included.

The researchers found that the average preoperative PSA values were significantly different between the TURP, HoLRP, and OP groups. Only one patient had incidental prostate cancer in the HoLRP group. No differences were present between the preoperative PSA values for patients with histologic BPH and those with incidental prostate cancer undergoing a watchful waiting strategy. However, the postoperative PSA values were increased in the patients with prostate cancer; similarly, patients with incidental prostate cancer had a significantly elevated postoperative mean PSA velocity compared with patients without prostate cancer. The researchers therefore concluded that postoperative PSA and PSA velocity measurements could be used to distinguish patients with prostate cancer from those with histologic BPH only. The study was published ahead of print on May 8, 2009, in the online edition of Urology.

Prostatic adenoma inevitably remains after BPH surgery, and studies have determined that the level of PSA decreases by approximately 0.1-0.3 ng/ml for every gram of prostate tissue removed. Therefore, PSA levels should indicate residual hyperplastic tissue, as well as resulting cancer risk.

Related Links:

Northwestern University



Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Radiofrequency Generator
GX1
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: Adobe Stock

New ECG Foundation Model Enables Broad Cardiac Diagnosis and Risk Prediction

Electrocardiograms are central to cardiovascular decision-making, but conventional artificial intelligence models are often trained for narrow tasks, such as detecting a single arrhythmia.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.